Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US

Journal of Medical Economics

Volumn 18, Issue 6, 2015, Pages 399-409

  Amin, Alpesh ^a   Bruno, Amanda ^b   Trocio, Jeffrey ^c   Lin, Jay ^d   Lingohr Smith, Melissa ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c PFIZER INC   (United States)

^d Novosys Health   (United States)

Author keywords

Economic model; Healthcare costs; New oral anticoagulants; Non valvular atrial fibrillation; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; EDOXABAN; PLACEBO; RIVAROXABAN; WARFARIN; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIDONE DERIVATIVE; THIAZOLE DERIVATIVE;

ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CLINICAL TRIAL; DRUG COST; HUMAN; SENSITIVITY ANALYSIS; UNITED STATES; VENOUS THROMBOEMBOLISM; CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; COST; COST BENEFIT ANALYSIS; ECONOMICS; EPIDEMIOLOGY; HEALTH CARE COST; HEART INFARCTION; LUNG EMBOLISM; STATISTICAL MODEL;

ANTICOAGULANTS; ATRIAL FIBRILLATION; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DABIGATRAN; HEALTH EXPENDITURES; HEMORRHAGE; HUMANS; MODELS, ECONOMETRIC; MYOCARDIAL INFARCTION; PULMONARY EMBOLISM; PYRAZOLES; PYRIDINES; PYRIDONES; RIVAROXABAN; STROKE; THIAZOLES; UNITED STATES; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 84935852808     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2015.1007210     Document Type: Article

References (53)

1. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006;114:119-25
2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5
3. Heit J, Cohen A, Anderson FJ. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. Blood 2005;106:267A
4. Reiffel JA. Atrial fibrillation and stroke: Epidemiology. Am J Med 2014;127:e15-16
5. Patel AA, Ogden K, Veerman M, et al. The economic burden to Medicare of stroke events in atrial fibrillation populations with and without thromboprophylaxis. Popul Health Manag 2014;17:159-65
6. Spyropoulos AC, Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: An administrative claims analysis from 30 managed care organizations. J Manag Care Pharm 2007;13:475-86
7. Lefebvre P, Laliberte? F, Nutescu EA, et al. All-cause and potentially diseaserelated health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries. J Manag Care Pharm 2012;18:363-74
8. Kim MH, Johnston SS, Chu BC, et al. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes 2011;4:313-20
9. Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet 2012;379:1835-46
10. Mahan CE, Borrego ME, Woersching AL, et al. Venous thromboembolism: Annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates. Thromb Haemost 2012;108:291-302
11. American College of Cardiology Foundation, American Heart Association, European Society of Cardiology, et al. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation 2013;127:1916-26
12. Kearon C, Akl EA, Comerota AJ, et al. American College of Chest Physicians. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis. 9th edn. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl): E419S-94S
13. Friedman RJ. Benefits of novel oral anticoagulant agents for thromboprophylaxis after total hip or knee arthroplasty. Am Health Drug Benefits 2012;5:115-22
14. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. New Engl J Med 2009;361:1139-51
15. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New Engl J Med 2011;365:883-91
16. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. New Engl J Med 2011;365:981-2
17. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093-104
18. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. Lancet 2014;383:955-62
19. Schulman S, Kearon C, Kakkar AK, et al; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-52
20. Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014;129:764-72
21. EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510
22. EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366:1287-97
23. Prins MH, Lensing AWA, Bauersachs R, et al; EINSTEIN Investigators. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: A pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 2013;11:21
24. Agnelli G, Buller HR, Cohen A, et al; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013;369:799-808
25. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369:1406-15
26. Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013;368:709-18
27. EINSTEIN Investigators, Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363: 2499-510
28. Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013;368:699-708
29. Bauer KA. Pros and cons of new oral anticoagulants. ASH Educ Book 2013;2013:464-70
30. Deitelzweig S, Amin A, Jing Y, et al. Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials. J Med Econ 2012;15:776-85
31. Amin A, Jing Y, Trocio J, et al. Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients. J Med Econ 2014;17:763-70
32. Amin A, Jing Y, Trocio J, et al. Evaluation of medical costs avoided when new oral anticoagulants are used for extended treatment of venous thromboembolism based on clinical trial results. J Thromb Thrombolysis Accepted. 2014.
33. Mercaldi CJ, Ciarametaro M, Hahn B, et al. Cost efficiency of anticoagulation with warfarin to prevent stroke in medicare beneficiaries with nonvalvular atrial fibrillation. Stroke 2011;42:112-18
34. Earnshaw SR, Scheiman J, Fendrick AM, et al. Cost-utility of aspirin and proton pump inhibitors for primary prevention. Arch Intern Med 2011;171:218-25
35. Spyropoulos AC, Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: An administrative claims analysis from 30 managed care organizations. J Manag Care Pharm 2007;13:475-86
36. Centers for Medicare and Medicaid Services. Medicare Fee Schedule, Payment and Reimbursement Benefit Guideline, CPT Code Billing. 2013. Centers for Medicare and Medicaid Services, Baltimore, MD. http://www.medicarepaymentandreimbursement. com/2013/12/medicare-scheduleupdate- important.html. Accessed August 25, 2014
37. Consumer Price Index December 2013. USDL-14-0037. Bureau of Labor Statistics US Department of Labor, Washington, DC. http://www.bls.gov/news.release/archives/cpi-01162014.pdf. Accessed August 25, 2014
38. Colilla S, Crow A, Petkun W, et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol 2013;112:1142-7
39. Laliberte? F, Pilon D, Raut MK, et al. Is rivaroxaban associated with lower inpatient costs compared to warfarin among patients with non-valvular atrial fibrillation? Curr Med Res Opin 2014;30:1521-8
40. Deitelzweig SB, Johnson BH, Lin J, et al. Prevalence of clinical venous thromboembolism in the USA: Current trends and future projections. Am J Hematol 2011;86:217-20
41. Chiong JR, Kim S, Lin J, et al. Evaluation of costs associated with tolvaptanmediated length of stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial. J Med Econ 2012;15:1-9
42. Dasta JF, Chiong JR, Christian R, et al. Evaluation of costs associated with tolvaptan- mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT-1 and SALT-2 trials. Hospit Pract 2012;40:1-8.
43. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991;22:983-8
44. Mercaldi CJ, Ciarametaro M, Hahn B, et al. Cost efficiency of anticoagulation with warfarin to prevent stroke in medicare beneficiaries with nonvalvular atrial fibrillation. Stroke 2011;42:112-18
45. Casciano JP, Dotiwala J, Martin BC. The costs of warfarin underuse and nonadherence in patients with atrial fibrillation: A commercial insurer perspective. J Manag Care Pharm 2013;19:302-16
46. Zimetbaum PJ, Thosani A, Yu H, et al. Are atrial fibrillation patients receiving warfarin in accordance with stroke risk? Am J Med 2010;123:446-53
47. Ansell JE, Hughes R. Evolving models of warfarin management: Anticoagulation clinics, patient self-monitoring, and patient self-management. Am Heart J 1996;132:1095-100
48. Melamed OC, Horowitz G, Elhayany A, et al. Quality of anticoagulation control among patients with atrial fibrillation. Am J Manag Care 2011;17:232-7
49. Spencer FA, Emery C, Joffe SW, et al. Incidence rates, clinical profile, and outcomes of patients with venous thromboebolism. The Worcester VTE study. J Thromb Thrombolysis 2009;28:401-9
50. Hansson PO, So? rbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: Incidence and risk factors. Arch Intern Med 2000;160:769-74
51. Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 2007;92: 199-205
52. Analy$ource Online. First Databank Inc. DMD America, Syracuse, NY. 2013
53. Health care costs: A primer. Kaiser Family Foundation. Menlo Park, CA, 2012. http://kff.org/report-section/health-care-costs-a-primer-2012-report/. Accessed August 25, 2014